ASCO 2021 | Enfortumab vedotin in urothelial cancer

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the Phase Ib EV-103 trial (NCT03288545) assessing enfortumab vedotin in combination with other therapies in urothelial cancer (UC), and the Phase III EV-301 trial (NCT03474107) assessing enfortumab vedotin versus chemotherapy in UC. Despite a small cohort of 45 patients, the overall survival was reached in the EV-103 trial, and an additional existing cohort will evaluate the contribution of pembrolizumab. The EV-301 aims to investigate whether enfortumab vedotin can replace chemotherapy as first line therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting